Left Ventricular ThrombusLVT RegistryNCT06963567
Left Ventricular Thrombus Registry
An observational study of Left Ventricular Thrombus, run by Queen Mary University of London at 8 sites in United Kingdom.
Trial summary
Left Ventricular Thrombus (LVT) is a blood clot that can develop in a poorly functioning heart. In around 1 in 6 patients who have had a heart attack or diagnosed with heart failure tend to develop blood clots in their main heart chamber. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Left Ventricular Thrombus
- How many people
- 1,500 participants
- Where
- 8 sitesUnited Kingdom
- Study dates
- 17 May 2024to 31 Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with a diagnosis of LV thrombus in the setting of LV dysfunction (acute myocardial infarction, Ischaemic Cardiomyopathy (ICM), dilated cardiomyopathy (DCM)) will be screened. Patients that do not have LV thrombus but are at risk for developing thrombus such as those with severe LV dysfunction, LV aneurysms, large territory infarcts will also be included.
Who may be able to join
- Patients with LV thrombus or;
- Patients at risk for developing LV thrombus (e.g severe LV dysfunction, LV aneurysm, MI.
Who cannot join
- Age < 18 years
- Unable to consent
Trial locations and contacts
8 sites in 1 country. Contact the study team or a site near you to ask about taking part.
8 sites in 1 country
United Kingdom8 sites, 8 recruiting
- Recruiting
Lancashire Cardiac Centre
Blackpool, FY3 8NR
Tawfiq Choudhury, 01253 955547, bfwh.randd.office@nhs.net
bfwh.randd.office@nhs.net
- Recruiting
Royal Papworth Hospital
Cambridge, Cambridgeshire, CB2 0AY
Paul Bambrough, 01223 638000, papworth.randdenquiries@nhs.net
01223 638000, papworth.randdenquiries@nhs.net
- Recruiting
Leeds General Infirmary
Leeds, LS1 3EX
Arka Das, 0113 206 0469, leedsth-tr.researchfacilitation@nhs.net
Arka Das
- Not yet recruiting
Basildon University Hospital
London, Essex, SS16 5NL
Richard Jones, 0300 443 6162, mse.researchenquiries@nhs.net
0300 443 6162, mse.researchenquiries@nhs.net
- Recruiting
St Bartholomew's Hospital
London, EC1A 7BE
Mervyn Andiapen, 020 3765 8707, mervyn.andiapen@nhs.net
Dr Dan Jones
- Recruiting
Imperial College Healthcare London
London, W12 0HS
Adam Hartley, +44 (0)20 3313 8070, imperial.admin_trustresearchcontracts@nhs.net
+44 (0)20 3313 8070, imperial.admin_trustresearchcontracts@nhs.net
- Not yet recruiting
James Cook University Hospital
Middlesbrough, North Yorkshire, TS4 3BW
David Austin, 01642 850850, stees.tvra.admin@nhs.net
01642 850850, stees.tvra.admin@nhs.net
- Not yet recruiting
Sunderland Royal Hospital
Sunderland, Tyne and Wear, SR4 7TP
Alykhan Bandali, 0191 4041000, stsft.research@nhs.net
0191 4041000, stsft.research@nhs.net
About this study
Official title: Observational Registry to Determine the Predictors and Outcomes of Patients at Risk of and Diagnosed With Left Ventricular Thrombus
Left Ventricular Thrombus (LVT) is a blood clot that can develop in a poorly functioning heart. In around 1 in 6 patients who have had a heart attack or diagnosed with heart failure tend to develop blood clots in their main heart chamber.
Having a blot clot in the main heart chamber can lead to serious complications such as stroke. Treatment for blood clots is blood thinning medications, which if taken for a prolonged period of time can result in bleeding which further complicates treatment. We hope to gather information to better understand the factors associated with blood clot formation and management in the lower left chamber of the heart. This understanding will hopefully enable us and others to improve management of this condition in the future and therefore help the wider population. As part of this study, bloods and scan results will be recorded and we will complete a short quality of life questionnaire. When participants come in for routine MRI scan, we may capture additional images for further research analysis.
A sample of blood no more than one tablespoon will be collected for research analysis at the same time as routine blood test. This will occur at baseline and at around 6 months. At 12 months we will repeat the quality of life questionnaire and collect final data.
- Conditions
- Left Ventricular Thrombus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| LV Thrombus (present) | Patients with a diagnosis of LV thrombus in the setting of LV dysfunction (acute myocardial infarction, Ischaemic Cardiomyopathy (ICM), dilated cardiomyopathy (DCM)). | |
| LV Thrombus (at risk) | Patients that do not have LV thrombus but are at risk for developing thrombus such as those with severe LV dysfunction, LV aneurysms, large territory infarcts will also be included. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite Result
To measure the composite result of major bleeding (BARC >3), stroke and systemic embolisation, and all-cause mortality
Measured: From baseline to final 12 month follow up (+/- 2 months)
Secondary outcomes (3)
CMR prediction of thrombus
To assess CMR based risk prediction model of recurrence of LV thrombus
Measured: From baseline to 6 month follow up (+/- 3 months)
Blood Test
To assess blood test variables in the persistence or recurrence of LV thrombus
Measured: From baseline to 6 month follow up (+/- 3 months)
Quality of Life Questionnaire
Participants quality of life (QoL) will be measured using European Quality of Life-5 Dimensions - 5 levels (EQ-5D-5L) questionnaire at baseline and 12 months
Measured: From baseline to final 12 month follow up (+/- 2 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2025
- Study start17 May 2024
- Primary completion31 Jan 2027 (estimated)
- Study completion31 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Left Ventricular ThrombusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Queen Mary University of London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06963567
- Sponsor's protocol ID
- 336025
- Other IDs
- G-002409
- Acronym
- LVT Registry
- Status last verified
- Jul 2026
- First submitted
- 30 Apr 2025
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Registry to Determine the Predictors and Outcomes of Patients at Risk of and Diagnosed With Left Ventricular Thrombus
- ClinicalTrials.gov ID
- NCT06963567
- Acronym / sponsor ID
- LVT Registry / 336025
- Conditions
- Left Ventricular Thrombus
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- Queen Mary University of LondonUniversity, hospital or other
- Study start
- 17 May 2024 (actual)
- Primary completion
- 31 Jan 2027 (estimated)
- Study completion
- 31 Jan 2027 (estimated)
- First posted
- 9 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Left Ventricular Thrombus (LVT) is a blood clot that can develop in a poorly functioning heart. In around 1 in 6 patients who have had a heart attack or diagnosed with heart failure tend to develop blood clots in their main heart chamber.
Having a blot clot in the main heart chamber can lead to serious complications such as stroke. Treatment for blood clots is blood thinning medications, which if taken for a prolonged period of time can result in bleeding which further complicates treatment. We hope to gather information to better understand the factors associated with blood clot formation and management in the lower left chamber of the heart. This understanding will hopefully enable us and others to improve management of this condition in the future and therefore help the wider population. As part of this study, bloods and scan results will be recorded and we will complete a short quality of life questionnaire. When participants come in for routine MRI scan, we may capture additional images for further research analysis.
A sample of blood no more than one tablespoon will be collected for research analysis at the same time as routine blood test. This will occur at baseline and at around 6 months. At 12 months we will repeat the quality of life questionnaire and collect final data.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| LV Thrombus (present) | – | –Patients with a diagnosis of LV thrombus in the setting of LV dysfunction (acute myocardial infarction, Ischaemic Cardiomyopathy (ICM), dilated cardiomyopathy (DCM)). |
| LV Thrombus (at risk) | – | –Patients that do not have LV thrombus but are at risk for developing thrombus such as those with severe LV dysfunction, LV aneurysms, large territory infarcts will also be included. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with a diagnosis of LV thrombus in the setting of LV dysfunction (acute myocardial infarction, Ischaemic Cardiomyopathy (ICM), dilated cardiomyopathy (DCM)) will be screened. Patients that do not have LV thrombus but are at risk for developing thrombus such as those with severe LV dysfunction, LV aneurysms, large territory infarcts will also be included.
Key inclusion criteria (2 listed)
- Patients with LV thrombus or;
- Patients at risk for developing LV thrombus (e.g severe LV dysfunction, LV aneurysm, MI.
Key exclusion criteria (2 listed)
- Age < 18 years
- Unable to consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Composite Result
Time frame: From baseline to final 12 month follow up (+/- 2 months)
To measure the composite result of major bleeding (BARC >3), stroke and systemic embolisation, and all-cause mortality
3 secondary outcomes
CMR prediction of thrombus
Time frame: From baseline to 6 month follow up (+/- 3 months)
Blood Test
Time frame: From baseline to 6 month follow up (+/- 3 months)
Quality of Life Questionnaire
Time frame: From baseline to final 12 month follow up (+/- 2 months)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Left Ventricular Thrombus
Not yet recruitingPhase 3
SWITCH: Apixaban vs Vitamin K in HM3
LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure
RecruitingPhase 3
Apixaban Versus Warfarin for Left Ventricular Thrombus
Left Ventricular Thrombus
Not yet recruitingPhase 4
STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump
LVAD (Left Ventricular Assist Device) Thrombosis, LVAD
Recruiting
Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction
ST-segment Elevation Myocardial Infarction (STEMI), Left Ventricular Thrombus
RecruitingPhase 4
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device
Bleeding, Clot Blood
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Left Ventricular Thrombus, run by Queen Mary University of London at 8 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite Result (time frame: From baseline to final 12 month follow up (+/- 2 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.